Last reviewed · How we verify

Bupivacaine-fentanyl elective group

Conrad Arnfinn Bjørshol · FDA-approved active Small molecule

Bupivacaine is a local anesthetic that blocks sodium channels in nerve fibers, while fentanyl is an opioid agonist that binds to mu opioid receptors to provide analgesia, together delivering regional anesthesia and analgesia for elective procedures.

Bupivacaine is a local anesthetic that blocks sodium channels in nerve fibers, while fentanyl is an opioid agonist that binds to mu opioid receptors to provide analgesia, together delivering regional anesthesia and analgesia for elective procedures. Used for Regional anesthesia and analgesia for elective surgical procedures.

At a glance

Generic nameBupivacaine-fentanyl elective group
SponsorConrad Arnfinn Bjørshol
Drug classLocal anesthetic with opioid analgesic combination
TargetVoltage-gated sodium channels (bupivacaine); mu opioid receptor (fentanyl)
ModalitySmall molecule
Therapeutic areaAnesthesia and Pain Management
PhaseFDA-approved

Mechanism of action

Bupivacaine works by inhibiting sodium influx through voltage-gated sodium channels in nerve cell membranes, preventing depolarization and blocking pain signal transmission in the targeted region. Fentanyl enhances analgesia by activating mu opioid receptors in the central and peripheral nervous system. This combination provides both local anesthetic blockade and systemic opioid analgesia for perioperative pain management.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: